Huda Salem Al-Salem

Dr. Huda Salem Al-Salem


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2020 in Molecules
Verified
Journal Article
Open access
PDF file
HAHuda Salem Al-Salem
Huda Salem Al-Salem
MAMd Arifuzzaman
Md Arifuzzaman
HAHamad Alkahtani
Hamad Alkahtani
Ashraf N. AbdallaAshraf N. Abdalla
Ashraf N. Abdalla
IIIman S. Issa
Iman S. Issa
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
Isatin derivatives potentially act on various biological targets. In this article, a series of novel isatin-hydrazones were synthesized in excellent yields. Their cytotoxicity was tested against human breast adenocarcinoma (MCF7) and human ovary adenocarcinoma (A2780) cell lines using MTT assay. Compounds 4j (IC50 = 1.51 ± 0.09 µM) and 4k (IC50 = 3.56 ± 0.31) showed excellent activity against MCF7, whereas compound 4e showed considerable cytotoxicity against both tested cell lines, MCF7 (IC50 = 5.46 ± 0.71 µM) and A2780 (IC50 = 18.96± 2.52 µM), respectively. Structure-activity relationships (SARs) revealed that, halogen substituents at 2,6-position of the C-ring of isatin-hydrazones are the most potent derivatives. In-silico absorption, distribution, metabolism and excretion (ADME) results demonstrated recommended drug likeness properties. Compounds 4j (IC50 = 0.245 µM) and 4k (IC50 = 0.300 µM) exhibited good inhibitory activity against the cell cycle regulator CDK2 protein kinase compared to imatinib (IC50 = 0.131 µM). A molecular docking study of 4j and 4k confirmed both compounds as type II ATP competitive inhibitors that made interactions with ATP binding pocket residues, as well as lacking interactions with active state DFG motif residues.

21 April 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
HAHuda Salem Al-Salem
Huda Salem Al-Salem
MAMd Arifuzzaman
Md Arifuzzaman
IIIman S. Issa
Iman S. Issa
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
Recently, we have reported a series of isatin hydrazone, two of them, namely, 3-((2,6-dichlorobenzylidene)hydrazono)indolin-2-one (1) and 3-((2-chloro-6-fluorobenzylidene)hydrazono)indolin-2-one (2) having potent cytotoxicity, showing cyclin-dependent kinases (CDK2) inhibitory activity and bearing recommended drug likeness properties. Since both compounds (1 and 2) showed inhibitory activity against CDK2, we assumed it would also have multiple receptor tyrosine kinases (RTKs) inhibitory activity. Considering those points, here, above-mentioned two isatin hydrazone 1 and 2 were synthesized using previously reported method for further investigation of their potency on RTKs (EGFR, VEGFR-2 and FLT-3) inhibitory activity. As expected, Compound 1 exhibited excellent inhibitory activity against epidermal growth factor receptor (EGFR, IC50 = 0.269 µM), vascular epidermal growth factor receptor 2 (VEGFR-2, IC50 = 0.232 µM) and FMS-like tyrosine kinase-3 (FLT-3, IC50 = 1.535 µM) tyrosine kinases. On the other hand, Compound 2 also exhibited excellent inhibitory activity against EGFR (IC50 = 0.369 µM), VEGFR-2 (IC50 = 0.266 µM) and FLT-3 (IC50 = 0.546 µM) tyrosine kinases. A molecular docking study with EGFR, VEGFR-2 and FLT-3 kinase suggested that both compounds act as type I ATP competitive inhibitors against EGFR and VEGFR-2, and type II ATP non-competitive inhibitors against FLT-3.

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
TMTebyan O. Mirgany
Tebyan O. Mirgany
Ashraf N. AbdallaAshraf N. Abdalla
Ashraf N. Abdalla
ARArifuzzaman
Arifuzzaman
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
HAHuda Salem Al-Salem
Huda Salem Al-Salem
A series of quinazolin-4(3H)-one derivatives were synthesised and evaluated for their cytotoxicity against human Caucasian breast adenocarcinoma (MCF-7) and human ovarian carcinoma (A2780) cell lines. Cytotoxicity of the most tested compounds was 2- to 30-fold more than the positive control lapatinib (IC50 of 2j = 3.79 ± 0.96; 3j = 0.20 ± 0.02; and lapatinib = 5.9 ± 0.74) against MCF7 cell lines except two compounds (IC50 of 2 b = 15.72 ± 0.07 and 2e = 14.88 ± 0.99). On the other hand, cytotoxicity was 4 − 87 folds (IC50 of 3a = 3.00 ± 1.20; 3 g = 0.14 ± 0.03) more the positive control lapatinib (IC50 = 12.11 ± 1.03) against A2780 cell lines except compound 2e (IC50 = 16.43 ± 1.80). Among the synthesised quinazolin-4(3H)-one derivatives, potent cytotoxic 2f-j and 3f-j were investigated for molecular mechanism of action. Inhibitory activities of the compounds were tested against multiple tyrosine protein kinases (CDK2, HER2, EGFR and VEGFR2) enzymes. As expected, all the quinazolin-4(3H)-one derivatives were showed comparable inhibitory activity against those kinases tested, especially, compound 2i and 3i showed potent inhibitory activity against CDK2, HER2, EGFR tyrosine kinases. Therefore, molecular docking analysis for quinazolin-4(3H)-one derivatives 2i and 3i were performed, and it was revealed that compounds 2i and 3i act as ATP non-competitive type-II inhibitor against CDK2 kinase enzymes and ATP competitive type-I inhibitor against EGFR kinase enzymes. However, in case of HER2, compounds 2i act as ATP non-competitive type-II inhibitor and 3i act as ATP competitive type-I inhibitor. Docking results of known inhibitors were compared with synthesised compounds and found synthesised 2i and 3i are superior than the known inhibitors in case of interactions. In addition, in silico drug likeness properties of quinazolin-4(3H)-one derivatives showed better predicted ADME values than lapatinib.

26 May 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
HAHuda Salem Al-Salem
Huda Salem Al-Salem
HAHatem Abuelizz
Hatem Abuelizz
IIIman S. Issa
Iman S. Issa
AMAmany Z. Mahmoud
Amany Z. Mahmoud
AAAli Alhoshani
Ali Alhoshani
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
Developing anticancer therapeutics with no/few side effects is a challenge for medicinal chemists. The absence of antibacterial activity of an anticancer drug removes its detrimental effect toward intestinal flora and therefore leads to reduced side effects. Here, a series of novel N-benzylisatin-aryl-hydrazones was designed, synthesized and evaluated for their antimicrobial and antiproliferative activities with SAR and ADME studies, aiming to develop anticancer drugs with no antimicrobial, yet high antiproliferative activities. The results were then compared with the effects of first-line treatments for lung cancer drug Gefitinib. Novel N-benzylisatin-aryl-hydrazones were synthesized from isatin and benzyl bromide in three steps with good to moderate yields. Antimicrobial activity was tested with six Gram-positive/negative bacterial strains, antifungal activity with a fungal strain and antiproliferative activity against ‘A549’ and ‘HeLa cell lines’, respectively. As expected, synthesized hydrazones reveled no effects on any of the strains of bacteria and fungi up to 100-µg/disc concentration. However, four compounds showed two-to-four fold antiproliferative activity over Gefitinib. For instance, IC50 of a compound (6c) shows concentration of 4.35 µM, whereas gefitinib shows 15.23 µM against ‘A549.’ ADME predicted studies reveled that our synthesized hydrazones exhibited higher ADME values than the Gefitinib. Therefore, our synthesized hydrazones can be an excellent scaffold for the development of anticancer therapeutics after considering further investigations.

28 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DADuaa A. Aqeel
Duaa A. Aqeel
HAHaneen Abdullah AL-Mazroua
Haneen Abdullah AL-Mazroua
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
HAHatun Alomar
Hatun Alomar
ABAhmed H. Bakheit
Ahmed H. Bakheit
HAHuda Salem Al-Salem
Huda Salem Al-Salem
Finding an effective treatment for autism spectrum disorder (ASD) requires a multifaceted approach. This includes the ability to remain in the digestive system to combat harmful microbes, pass through the bloodstream to neutralize free radicals, and cross the Blood-Brain Barrier (BBB). Crossing into the brain would inhibit certain enzymes, increase dopamine and serotonin levels, and reduce the byproducts of their interactions that contribute to neuroinflammation. In this work, we synthesized novel chalcone derivatives and examined their efficacy in inhibiting monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) to identify compounds that selectively inhibit MAO-B. After selecting four chalcone derivatives, these compounds underwent several tests, including testing their ability to interact with the active site within the enzyme (Molecular docking) and their affinity for it, and measuring their pharmacological properties in terms of solubility, absorption, plasma distribution, and penetration through both the gastrointestinal and blood-brain barriers. Given the gut-brain axis's importance in autism development, we conducted a hypothetical study to measure the compounds' interaction with two types of gut bacteria. The results showed that both selected compounds could promote the growth of beneficial bacteria and inhibit the growth of harmful bacteria in an in silico study. The safety of these compounds was later assessed by measuring their toxicity to living cells, paving the way for subsequent in vivo studies in laboratory animals. These tests were essential to ensure the compounds could withstand degradation and exert their intended effects at their target sites.

18 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DADuaa A. Aqeel
Duaa A. Aqeel
HAHaneen Abdullah AL-Mazroua
Haneen Abdullah AL-Mazroua
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
HAHatun Alomar
Hatun Alomar
ABAhmed H. Bakheit
Ahmed H. Bakheit
HAHuda Salem Al-Salem
Huda Salem Al-Salem
Background/Objectives: Autism spectrum disorder (ASD) lacks pharmacological therapies for its core features. This study synthesized chalcone derivatives, determined their monoamine oxidase A (MAO-A) and MAO-B inhibitory profiles, and generated computational hypotheses regarding MAO-B binding, gut–bacterial protein interactions, and drug-like properties. Methods: Sixteen chalcones (23–38; fifteen newly reported) were synthesized and characterized. MAO-A and MAO-B inhibition was measured using fluorometric concentration–response assays, with clorgyline and safinamide as references. Compounds 23, 26, 35, and 37 were docked against human MAO-B (PDB 2V5Z), Bacteroides fragilis profragilysin-3 (PDB 7POU), and Lacticaseibacillus casei thymidylate synthase (PDB 1LCA and 3IK1), and subjected to in silico ADMET assessment. Results: Compound 37 showed the best balance of MAO-B potency and selectivity, with an IC50 of 0.636 µM and a selectivity index of 16.65. Compound 35 was also MAO-B-selective (IC50 = 2.52 µM; selectivity index = 13.24). Compound 34 was the most potent dual inhibitor (MAO-A IC50 = 0.647 µM; MAO-B IC50 = 0.272 µM), whereas none met the predefined MAO-A-selectivity threshold. Docking suggested accommodation of the chalcones within the MAO-B cavity, the peripheral hesperetin-binding pocket of profragilysin-3, and the thymidylate-synthase folate/dUMP cleft. Predicted ADMET profiles indicated limited absorption, extensive protein binding, and potential hepatic and genotoxic liabilities. Conclusions: Compound 37 is the leading selective MAO-B scaffold, while compound 35 provides a second selective chemotype. The bacterial-target docking and ADMET findings are hypothesis-generating only and do not demonstrate effects on toxin activity, bacterial growth, microbiome composition, safety, central exposure, or ASD-related outcomes. Enzyme kinetics, target-engagement, permeability, genotoxicity, and microbiological studies are required before in vivo evaluation.